Veritas In Silico (TSE:130A) Interest Coverage: No Debt (1) (As of Dec. 2025) — 100% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:130A Veritas In Silico Inc TSE:130A
11 GF Score
Price 円418.00
! 4 Warning Signs
View Full Analysis

What is Veritas In Silico Interest Coverage?

Veritas In Silico TSE:130A -3.91% 11 Interest Coverage is No Debt (1) as of Dec. 2025, which is 100% below its 10-year median of 10,000.00. GuruFocus rates TSE:130A with a GF Score™ of 11/100. The stock has 4 warning signs investors should review. Among 376 Biotechnology companies, Veritas In Silico ranks better than 99.2% on this metric.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Veritas In Silico's Operating Income for the three months ended in Dec. 2025 was 円0.00 Mil. Veritas In Silico's Interest Expense for the three months ended in Dec. 2025 was 円0.00 Mil. Veritas In Silico has no debt. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Veritas In Silico Inc has no debt.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Veritas In Silico's Interest Coverage or its related term are showing as below:

TSE:130A' s Interest Coverage Range Over the Past 10 Years
Min: No Debt   Med: No Debt   Max: No Debt
Current: No Debt


TSE:130A's Interest Coverage is ranked better than
99.2% of 376 companies
in the Biotechnology industry
Industry Median: 104.025 vs TSE:130A: No Debt

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Veritas In Silico  (TSE:130A) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Veritas In Silico Interest Coverage Related Terms


Veritas In Silico Interest Coverage Historical Data

* Premium members only.

The historical data trend for Veritas In Silico's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Veritas In Silico Interest Coverage Chart

Veritas In Silico Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Interest Coverage
0.00 No Debt No Debt 0.00 No Debt

Veritas In Silico Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only No Debt No Debt No Debt No Debt No Debt

TSE:130A vs VRTX, REGN, ALNY: Interest Coverage Comparison

For the Biotechnology subindustry, Veritas In Silico's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veritas In Silico Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veritas In Silico's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Veritas In Silico's Interest Coverage falls into.


TSE:130A
11GF Score
Veritas In Silico Inc TSE:130A
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Veritas In Silico Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Veritas In Silico's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Veritas In Silico's Interest Expense was 円0.00 Mil. Its Operating Income was 円-396.75 Mil. And its Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.

Veritas In Silico had no debt (1).

Veritas In Silico's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Here, for the three months ended in Dec. 2025, Veritas In Silico's Interest Expense was 円0.00 Mil. Its Operating Income was 円0.00 Mil. And its Long-Term Debt & Capital Lease Obligation was 円0.00 Mil.

Veritas In Silico had no debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.

Frequently Asked Questions Learn more about Interest Coverage →
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Veritas In Silico (TSE:130A) has a Interest Coverage of No Debt (1) as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Veritas In Silico and its competitors. This is 100% below median its historical median of 10,000.00. Over the past decade, Veritas In Silico's Interest Coverage has ranged from 10,000.00 to 10,000.00. According to the industry distribution chart, Veritas In Silico ranks #3 out of 376 companies in the Biotechnology industry, placing it in the top 0.8%.
Is Veritas In Silico's Interest Coverage too high?
Veritas In Silico's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Over the past 10 years, this metric has ranged from a low of 10,000.00 to a high of 10,000.00. Based on the distribution chart, Veritas In Silico ranks #3 out of 376 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Veritas In Silico has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Veritas In Silico's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Veritas In Silico ranks #3 out of 376 companies for Interest Coverage. This places Veritas In Silico in the top 1% of its industry — outperforming the majority of peers. The industry median Interest Coverage is 104.03. Historically, Veritas In Silico's own Interest Coverage has ranged from 10,000.00 to 10,000.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Veritas In Silico and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Veritas In Silico's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Veritas In Silico stock overvalued right now?
Veritas In Silico (TSE:130A) has a current Interest Coverage of No Debt (1). The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Veritas In Silico's overall GF Score™ is 11/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Veritas In Silico (TSE:130A), the current Interest Coverage is No Debt (1) as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Veritas In Silico Business Description

Address 1-11-1, Nishigotanda, Shinagawa-ku, Tokyo, JPN, 141-0031
Veritas In Silico Inc is engaged in discovery of mRNA-targeted small molecule and antisense oligonucleotide drugs. It has ibVIS platform that combines informatics (i) and experimental biology at Veritas In Silico (VIS) that will bring to fruition mRNA-targeted drugs.
11GF Score

Get the complete analysis for TSE:130A

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円418.00
Price